# Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis

> **NCT02943447** · PHASE2 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 71 (actual)

## Conditions studied

- Primary Biliary Cholangitis

## Interventions

- **DRUG:** Cilofexor
- **DRUG:** Placebo to match cilofexor

## Key facts

- **NCT ID:** NCT02943447
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-12-01
- **Primary completion:** 2019-09-04
- **Final completion:** 2019-09-04
- **Target enrollment:** 71 (ACTUAL)
- **Why stopped:** The study was terminated because of the availability of alternate therapies for primary biliary cholangitis (PBC).
- **Last updated:** 2020-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02943447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02943447, "Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02943447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*